Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling

Although epidermal growth factor receptor (EGFR)-targeted therapy has improved clinical outcomes of patients with advanced non-small-cell lung cancer (NSCLC) carrying activating EGFR mutations, the development of acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), including the promi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Danlei, Zhao, Wen, Vallega, Karin A, Sun, Shi-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872905/
https://www.ncbi.nlm.nih.gov/pubmed/33574724
http://dx.doi.org/10.2147/LCTT.S293902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872905/
https://www.ncbi.nlm.nih.gov/pubmed/33574724
http://dx.doi.org/10.2147/LCTT.S293902

Ejemplares similares